Merck + Co., Inc.

Synaptic Pharmaceutical Corporation

Hanumath P Kari

Kamlesh P Vyas

Dhanapalan Nagarathnam

Ben E Evans

Bharat Lagu

Kanyin E Zhang

Donghui Cui

Michael Dunn

Margaret R Davis

This invention is directed to dihydropyrimidines which are selective antagonists for human &agr; receptors. This invention is also related to uses of these compounds for relaxing lower urinary tract tissue, treating benign prostatic hyperplasia and for the treatment of any disease where the antagonism of the &agr; receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Dihydropyrimidines and uses thereof

This invention is directed to dihydropyrimidines which are selective antagonists for human &agr;,receptors. This invention is also related to uses of these compounds for relaxing lower urinary tract tissue, treating benign prostatic hyperplasia and for the treatment of any disease where the antagonism of the &agr;,receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) or (II): ##STR1## and pharmaceutically acceptable salts thereof the compounds of the formula (II) in which R.sup.1 is hydrogen are disclosed.

Novel HMG-CoA reductase inhibitors

HMG-COA reductase inhibitors

Growing community of inventors

Hatfield, PA, United States of America

Hanumath P Kari